Galecto Reports First Quarter Operating and Financial Results
April 28, 2023 08:00 ET
|
Galecto, Inc.
BOSTON, April 28, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments...
Galecto to Present Two Posters at AACR Annual Meeting 2023
April 13, 2023 08:30 ET
|
Galecto, Inc.
BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments...
Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022
March 09, 2023 07:00 ET
|
Galecto, Inc.
BOSTON, March 09, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments...
Galecto to Participate in Oppenheimer’s 33rd Annual Healthcare Conference
March 02, 2023 16:05 ET
|
Galecto, Inc.
BOSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments...
Galecto to Participate in SVB Securities Global Biopharma Conference
February 01, 2023 08:00 ET
|
Galecto, Inc.
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments...
Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting
December 07, 2022 16:05 ET
|
Galecto, Inc.
Intermediate assessment of GB2064 in the Phase 2 myelofibrosis trial showed target engagement in the bone marrow and reduction in collagen fibrosis in four out of five evaluable patients GB2064 is...
Galecto Reports Third Quarter Operating and Financial Results
November 08, 2022 09:15 ET
|
Galecto, Inc.
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments...
Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients
November 08, 2022 06:00 ET
|
Galecto, Inc.
Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseasesFindings to be discussed in a conference call and virtual webinar...
Galecto to Participate in Jefferies London Healthcare Conference
November 03, 2022 08:00 ET
|
Galecto, Inc.
BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments...
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022
October 31, 2022 08:00 ET
|
Galecto, Inc.
Late-breaking oral and poster presentations include clinical and preclinical data related to GULLIVER-2 clinical trialGalecto to host a webinar at 8:00 a.m. ET on Tuesday, November 8, 2022 to discuss...